Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study

References

• Wroblewski L, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010;23:713–739.
   PubMed Web of Science ®Google Scholar
• Kwon YH, Heo J, Lee HS, et al. Failure of Helicobacter pylori eradication and age are independent risk factors for recurrent neoplasia after endoscopic resection of early gastric cancer in 283 patients. Aliment Pharmacol Ther. 2014;39:609–618.
   PubMed Web of Science ®Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–1153.
   PubMed Web of Science ®Google Scholar
• Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343–357.
   PubMed Web of Science ®Google Scholar
• Alarcon T, Domingo D, López-Brea M. Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents. 1999;12:19–26.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kim JI, Cheung DY, et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis. 2013;208:1123–1130.
   PubMed Web of Science ®Google Scholar
• Loffeld RJ, Werdmuller BF. Changes in antibiotic susceptibility of Helicobacter pylori in the course of eight years in the Zaanstreek region in the Netherlands. Gastroenterol Res Pract. 2013;2013:625937
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Pajares JM. Review article: Helicobacter pylori “rescue” regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002;16:1047–1057.
   PubMed Web of Science ®Google Scholar
• Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut. 2010;59:1465–1470.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol. 2014;20:10338–10347.
   PubMed Web of Science ®Google Scholar
• Yahav J, Samra Z, Niv Y, et al. Susceptibility-guided vs. empiric retreatment of Helicobacter pylori infection after treatment failure. Dig Dis Sci. 2006;51:2316–2321.
   PubMed Web of Science ®Google Scholar
• Lamouliatte H, Megraud F, Delchier JC, et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther. 2003;18:791–797.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kim N, Kim JM, et al. A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea. Scand J Gastroenterol. 2014;49:917–924.
   PubMed Web of Science ®Google Scholar
• Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter. 2010;15:38–45.
   PubMed Web of Science ®Google Scholar
• Yoon H, Kim N, Lee BH, et al. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter. 2009;14:77–85.
   PubMed Web of Science ®Google Scholar
• Kim JM, Kim JS, Jung HC, et al. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. Antimicrob Agents Chemother. 2004;48:4843–4847.
   PubMed Web of Science ®Google Scholar
• Kim JM, Kim JS, Kim N, et al. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother. 2005;56:965–967.
   PubMed Web of Science ®Google Scholar
• Hsueh PR, Ko WC, Wu JJ, et al. Consensus statement on the adherence to Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing Guidelines (CLSI-2010 and CLSI-2010-update) for Enterobacteriaceae in clinical microbiology laboratories in Taiwan. J Microbiol Immunol Infect. 2010;43:452–455
   PubMedGoogle Scholar
• Gerrits MM, van Vliet AH, Kuipers EJ, et al. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis. 2006;6:699–709.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Ianiro G, Bibbo S, et al. Culture-guided treatment approach for Helicobacter pylori infection: review of the literature. World J Gastroenterol. 2014;20:5205–5211.
   PubMed Web of Science ®Google Scholar
• Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013;18:206–214.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646–664.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Martino A, Pirozzi G, et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther. 2004;19:789–795.
   PubMed Web of Science ®Google Scholar
• Gasbarrini A, Ojetti V, Armuzzi A, et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2000;14:79–83.
   PubMed Web of Science ®Google Scholar
• Gomollon F, Sicilia B, Ducons JA, et al. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther. 2000;14:1335–1338.
   PubMed Web of Science ®Google Scholar
• Vicente R, Sicilia B, Gallego S, et al. Helicobacter pylori eradication in patients with peptic ulcer after two treatment failures: a prospective culture-guided study. Gastroenterol Hepatol. 2002;25:438–442.
   PubMedGoogle Scholar
• Graham DY, Dore MP. Helicobacter pylori therapy demystified. Helicobacter. 2011;16:343–345.
   PubMed Web of Science ®Google Scholar
• Oleastro M, Cabral J, Ramalho PM, et al. Primary antibiotic resistance of Helicobacter pylori strains isolated from Portuguese children: a prospective multicentre study over a 10 year period. J Antimicrob Chemother. 2011;66:2308–2311.
   PubMed Web of Science ®Google Scholar
• Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62:34–42.
   PubMed Web of Science ®Google Scholar
• Bardhan K, Bayerdorffer E, Veldhuyzen Van Zanten SJ, et al. The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter. 2000;5:196–201.
   PubMed Web of Science ®Google Scholar